KRAS and metastatic colorectal cancer: It is currently being tested in a Phase 1b/2 study along with the chemotherapeutic FOLFIRI and Avastin, which binds to vascular endothelial growth factor (VEGF) as a second-line treatment for metastatic colorectal cancer patients harboring KRAS mutations (Clinicaltrials.gov Identifier: NCT03829410 (accessed on 24 February 2021)).